Interventional, Open-label, Repeated Single-dose Trial Investigating the Effects of Enzyme Inhibition on the Pharmacokinetic Profile of Lu AF28996 and Its Metabolites in Healthy Participants
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Amoxicillin/clavulanic acid (Primary) ; Aspirin (Primary) ; Lu AF28996 (Primary) ; Mefenamic acid (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 10 Jun 2024 Status changed from active, no longer recruiting to completed.
- 02 May 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2024 Status changed from not yet recruiting to recruiting.